| 2.535 -0.015 (-0.59%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.3 | 1-year : | 3.64 |
| Resists | First : | 2.83 | Second : | 3.11 |
| Pivot price | 2.69  |
|||
| Supports | First : | 2.36 | Second : | 1.97 |
| MAs | MA(5) : | 2.51 |
MA(20) : | 2.71 |
| MA(100) : | 2.98 |
MA(250) : | 2.92 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 21.6 |
D(3) : | 18.5 |
| RSI | RSI(14): 38.1 |
|||
| 52-week | High : | 13.93 | Low : | 1.89 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ XBIO ] has closed above bottom band by 24.5%. Bollinger Bands are 4.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.64 - 2.65 | 2.65 - 2.66 |
| Low: | 2.49 - 2.51 | 2.51 - 2.53 |
| Close: | 2.51 - 2.54 | 2.54 - 2.56 |
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack distinct tumor neoantigens found in individual patients. Beyond this specialized area, the company actively engages in the discovery, investigation, and creation of advanced biologic medicines and cancer treatments. A significant part of its cell-based therapeutic endeavors involves therapies designed to target the B-cell receptor on the exterior of malignant tumor cells in specific patients, with the aim of addressing B-cell lymphomas. Furthermore, Xenetic capitalizes on its proprietary drug delivery technology, PolyXen, through strategic alliances with various biotechnology and pharmaceutical enterprises. The company has established important collaborative agreements with partners including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. has its headquarters located in Framingham, Massachusetts.
Sat, 01 Aug 2026
Xenetic Biosciences Inc (XBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Thu, 30 Jul 2026
Xenetic Biosciences Inc (XBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Thu, 30 Jul 2026
XBIO|Xenetic Biosciences Inc|Price:2.490|Chg%:+0.010 - TradingKey
Thu, 30 Jul 2026
Xenetic Biosciences Inc (XBIO) Institutional Confidence - TradingKey
Tue, 28 Jul 2026
Xenetic Biosciences Inc. (XBIO) Q2 2025 Earnings: EPS Beat Driven by Cost Discipline Amid Clinical-Stage Operations - dars.gov.et
Mon, 27 Jul 2026
Xenetic Biosciences Inc (XBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 15.7 (%) |
| Held by Institutions | 7.4 (%) |
| Shares Short | 19 (K) |
| Shares Short P.Month | 9 (K) |
| EPS | -1.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.23 |
| Profit Margin | -70.1 % |
| Operating Margin | -62.3 % |
| Return on Assets (ttm) | -21.9 % |
| Return on Equity (ttm) | -37.1 % |
| Qtrly Rev. Growth | 36 % |
| Gross Profit (p.s.) | 1.39 |
| Sales Per Share | 1.39 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -2.14 |
| PEG Ratio | 0 |
| Price to Book value | 0.78 |
| Price to Sales | 1.81 |
| Price to Cash Flow | -3.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|